



Ibrahim Yildiz is a Turkish doctor, medical oncologist, and professor. He sees and treats patients at Acıbadem Atakent Hospital in the Küçükçekmece district (Istanbul) and is engaged in academic work at Acıbadem Mehmet Ali Aydınlar University.
His main clinical focus is the treatment of lung cancer and other thoracic tumors. His inclusion on the board of directors of the lung cancer association confirms that this is precisely his area of strength.
He treats patients using chemotherapy, immunotherapy, targeted therapy, and hormonal therapy — all the main methods of modern medical oncology. For many tumors, he has experience in treatment according to international protocols: he is a member of ESMO and ASCO — the world’s leading oncology societies, which means his practice is synchronized with European and American standards.
He has been working in the Acıbadem group since 2015, before that at Izmir Katip Çelebi University. He publishes actively: more than 100 articles in international peer-reviewed journals according to his own statements; on Google Scholar — over 1,100 citations.
For a patient with lung cancer or other thoracic tumors, he is one of the well-founded choices in Istanbul: a medical oncologist with specialized expertise, an academic position, and a direct connection to international oncology standards.
Medical oncology (tıbbi onkoloji). Narrow focus — thoracic oncology: lung cancer, mediastinal tumors. According to the description on his own website and his position in the Lung Cancer Association, this is the main clinical focus.
He also treats patients with breast cancer, colorectal cancer, germ cell tumors of the testicles, soft tissue sarcomas, and other oncological diseases.

Acıbadem Atakent is one of the academic clinics of Acıbadem Healthcare Group, also serving as the teaching base of Acıbadem Mehmet Ali Aydınlar University. For a patient with lung cancer and other thoracic tumors, this is a practical choice: the clinic is equipped for a full cycle of oncology treatment — from diagnostics (CT, MRI, PET-CT, bronchoscopy) to chemotherapy, immunotherapy, targeted therapy, and supportive methods. A particular feature of Acıbadem is its multidisciplinary approach: the treatment plan is discussed by an oncology council that includes a medical oncologist, thoracic surgeon, radiation oncologist, radiologist, and pathologist. For lung cancer, this is critical, since the choice of method depends on the stage, histological type, and molecular profile of the tumor. The clinic actively applies modern methods of molecular tumor testing and selects targeted therapy based on mutations (EGFR, ALK, ROS1, PD-L1, and others), which is especially important in non-small cell lung cancer. For international patients, Acıbadem provides a standard support protocol: remote consultation, translation of medical documents, treatment coordinator, and a translator at appointments.
